Make Informed Investment Decisions with Affordable Access to Experts
Evaluating the Chances of Approval and Market Potential of Ariad's Brigatinib in ALK-Positive Non-Small Cell Lung Cancer Before PDUFA of April 29thTicker(s): ARIA, TKPYY, PFE, NVS, RHHBY, Genentech
An oncologist or pulmonologist with experience treating patients with ALK-positive non-small cell lung cancer, and knowledge of the data surrounding Brigatinib.
Please describe your background and experience treating patients with ALK-positive NCSCLC.Added By: pjloria
About how many patients are you currently seeing in your practice, and how many are on an effective treatment regimen?Added By: pjloria
Can you discuss other approved products for the space, including Pfizer's Xalkori, Novartis' Zykadia, and Genentech's Alecensa? How many of your patients currently take these products and how would you describe their safety and efficacy?Added By: pjloria
How does Brigatinib compare to these current treatments in terms of safety and efficacy? Please discuss any differences in mechanism of action, safety, and efficacy between these drugsAdded By: pjloria
What do you think of the chances of approval for Brigatinib on April 29th?Added By: pjloria
How much of the market share do you think Brigatinib will capture assuming it is approved? Does it have potential to be a major treatment or fit a niche need in the space?Added By: pjloria
How do you see the market share for these products evolving over the next couple of years? Will one of these products dominate the market?Added By: pjloria
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- PDUFA Date of April 29th for Ariad's (ARIA) Brigatinib in ALK-Positive Non-Small Cell Lung Cancer (NSCLC) TKPYY, ARIA Occurred On: Apr 28, 2017